{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T23:46:04Z","timestamp":1784245564980,"version":"3.55.0"},"reference-count":95,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T00:00:00Z","timestamp":1686528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"ICMR-NIV, Pune"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Human cytomegalovirus (HCMV) remains an essential global concern due to its distinct life cycle, mutations and latency. As HCMV is a herpesvirus, it establishes a lifelong persistence in the host through a chronic state of infection. Immunocompromised individuals are at risk of significant morbidity and mortality from the virus. Until now, no effective vaccine has been developed to combat HCMV infection. Only a few antivirals targeting the different stages of the virus lifecycle and viral enzymes are licensed to manage the infection. Therefore, there is an urgent need to find alternate strategies to combat the infection and manage drug resistance. This review will provide an insight into the clinical and preclinical antiviral approaches, including HCMV antiviral drugs and nucleic acid-based therapeutics.<\/jats:p>","DOI":"10.3390\/v15061358","type":"journal-article","created":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T01:35:30Z","timestamp":1686620130000},"page":"1358","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["An Update on Current Antiviral Strategies to Combat Human Cytomegalovirus Infection"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6533-6574","authenticated-orcid":false,"given":"Kingshuk","family":"Panda","sequence":"first","affiliation":[{"name":"Dengue-Chikungunya Group, Indian Council of Medical Research-National Institute of Virology, Pune 411001, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2688-3684","authenticated-orcid":false,"given":"Deepti","family":"Parashar","sequence":"additional","affiliation":[{"name":"Dengue-Chikungunya Group, Indian Council of Medical Research-National Institute of Virology, Pune 411001, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1517-0454","authenticated-orcid":false,"given":"Rajlakshmi","family":"Viswanathan","sequence":"additional","affiliation":[{"name":"Bacteriology Group, Indian Council of Medical Research-National Institute of Virology, Pune 411001, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Gatherer, D., Depledge, D.P., Hartley, C.A., Szpara, M.L., Vaz, P.K., Benk\u0151, M., Brandt, C.R., Bryant, N.A., Dastjerdi, A., and Doszpoly, A. (2021). ICTV virus taxonomy profile: Herpesviridae 2021. J. Gen. Virol., 102.","DOI":"10.1099\/jgv.0.001673"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1146\/annurev-virology-110615-042422","article-title":"Human cytomegalovirus latency: Approaching the Gordian knot","volume":"3","author":"Goodrum","year":"2016","journal-title":"Annu. Rev. Virol."},{"key":"ref_3","unstructured":"Fields, B.N. (2007). Fields\u2019 Virology, Lippincott Williams & Wilkins."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1172\/JCI45449","article-title":"Cytomegalovirus: Pathogen, paradigm, and puzzle","volume":"121","author":"Boeckh","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"578","DOI":"10.5694\/mja14.00183","article-title":"Cytomegalovirus disease in immunocompetent adults","volume":"201","author":"Lancini","year":"2014","journal-title":"Med. J. Aust."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Al Mana, H., Yassine, H.M., Younes, N.N., Al-Mohannadi, A., Al-Sadeq, D.W., Alhababi, D., Nasser, E.A., and Nasrallah, G.K. (2019). The current status of cytomegalovirus (CMV) prevalence in the MENA region: A systematic review. Pathogens, 8.","DOI":"10.3390\/pathogens8040213"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e2034","DOI":"10.1002\/rmv.2034","article-title":"Estimation of the worldwide seroprevalence of cytomegalovirus: A systematic review and meta-analysis","volume":"29","author":"Zuhair","year":"2019","journal-title":"Rev. Med. Virol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/rmv.655","article-title":"Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection","volume":"20","author":"Cannon","year":"2010","journal-title":"Rev. Med. Virol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0255-0857(21)01744-8","article-title":"Cytomegalovirus infection: An Indian perspective","volume":"27","author":"Chakravarti","year":"2009","journal-title":"Indian J. Med. Microbiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1128\/CMR.00062-12","article-title":"The \u201csilent\u201d global burden of congenital cytomegalovirus","volume":"26","author":"Manicklal","year":"2013","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0163-7258(03)00034-2","article-title":"The human cytomegalovirus","volume":"98","author":"Landolfo","year":"2003","journal-title":"Pharmacol. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Mancebo, F.J., Parras-Molt\u00f3, M., Garc\u00eda-R\u00edos, E., and P\u00e9rez-Romero, P. (2022). Deciphering the Potential Coding of Human Cytomegalovirus: New Predicted Transmembrane Proteome. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23052768"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1126\/science.1227919","article-title":"Decoding human cytomegalovirus","volume":"338","author":"Weisburd","year":"2012","journal-title":"Science"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"10960","DOI":"10.1128\/JVI.78.20.10960-10966.2004","article-title":"Identification of proteins in human cytomegalovirus (HCMV) particles: The HCMV proteome","volume":"78","author":"Varnum","year":"2004","journal-title":"Virol. J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12985-020-1296-4","article-title":"MicroRNAs expressed by human cytomegalovirus","volume":"17","author":"Zhang","year":"2020","journal-title":"Virol. J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-540-77349-8_1","article-title":"Human cytomegalovirus genome","volume":"325","author":"Murphy","year":"2008","journal-title":"Hum. Cytomegal."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Yu, X., Jih, J., Jiang, J., and Zhou, Z.H. (2017). Atomic structure of the human cytomegalovirus capsid with its securing tegument layer of pp150. Science, 356.","DOI":"10.1126\/science.aam6892"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1159\/000322141","article-title":"Human cytomegalovirus (HCMV)\u2013revised","volume":"37","author":"Schottstedt","year":"2010","journal-title":"Transfus. Med. Hemother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/cmi.12077","article-title":"Analysis of human cytomegalovirus secondary envelopment by advanced electron microscopy","volume":"15","author":"Schauflinger","year":"2013","journal-title":"Cell. Microbiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"11881","DOI":"10.1128\/JVI.74.24.11881-11892.2000","article-title":"Complex formation by human cytomegalovirus glycoproteins M (gpUL100) and N (gpUL73)","volume":"74","author":"Mach","year":"2000","journal-title":"Virol. J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4591","DOI":"10.1128\/JVI.80.9.4591-4600.2006","article-title":"Human cytomegalovirus infection elicits a glycoprotein M (gM)\/gN-specific virus-neutralizing antibody response","volume":"80","author":"Shimamura","year":"2006","journal-title":"Virol. J."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Kropff, B., Burkhardt, C., Schott, J., Nentwich, J., Fisch, T., Britt, W., and Mach, M. (2012). Glycoprotein N of human cytomegalovirus protects the virus from neutralizing antibodies. PLoS Pathog., 8.","DOI":"10.1371\/journal.ppat.1002999"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"18153","DOI":"10.1073\/pnas.0509201102","article-title":"Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism","volume":"102","author":"Wang","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Ciferri, C., Chandramouli, S., Leitner, A., Donnarumma, D., Cianfrocco, M.A., Gerrein, R., Friedrich, K., Aggarwal, Y., Palladino, G., and Aebersold, R. (2015). Antigenic characterization of the HCMV gH\/gL\/gO and pentamer cell entry complexes reveals binding sites for potently neutralizing human antibodies. PLoS Pathog., 11.","DOI":"10.1371\/journal.ppat.1005230"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/978-3-540-77349-8_4","article-title":"Cytomegalovirus cell tropism","volume":"325","author":"Sinzger","year":"2008","journal-title":"Hum. Cytomegal."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Gugliesi, F., Coscia, A., Griffante, G., Galitska, G., Pasquero, S., Albano, C., and Biolatti, M. (2020). Where do we stand after decades of studying human cytomegalovirus?. Microorganisms, 8.","DOI":"10.3390\/microorganisms8050685"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1111\/j.1600-6143.2009.02824.x","article-title":"The \u2018indirect\u2019effects of cytomegalovirus infection","volume":"9","author":"Freeman","year":"2009","journal-title":"Am. J. Transplant."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ejcdt.2013.09.022","article-title":"The impact of cytomegalovirus infection on mechanically ventilated patients in the respiratory and geriatric intensive care units","volume":"63","author":"Osman","year":"2014","journal-title":"Egypt. J. Chest Dis. Tuberc."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e1937","DOI":"10.1542\/peds.2013-0076","article-title":"Breast milk\u2013acquired cytomegalovirus infection and disease in VLBW and premature infants","volume":"131","author":"Lanzieri","year":"2013","journal-title":"Pediatrics"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1046\/j.1365-2249.2000.01138.x","article-title":"Cytomegalovirus immune globulin intravenous (human) administration modulates immune response to alloantigens in sensitized renal transplant candidates","volume":"119","author":"Sivasai","year":"2000","journal-title":"Clin. Exp. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e13655","DOI":"10.1111\/ctr.13655","article-title":"The use of CMVIg rescue therapy in cardiothoracic transplantation: A single-center experience over 6 years (2011\u20132017)","volume":"33","author":"Santhanakrishnan","year":"2019","journal-title":"Clin. Transplant."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e01794-16","DOI":"10.1128\/AAC.01794-16","article-title":"Phase 2 randomized, double-blind, placebo-controlled trial of RG7667, a combination monoclonal antibody, for prevention of cytomegalovirus infection in high-risk kidney transplant recipients","volume":"61","author":"Ishida","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1001\/jama.1987.03390220080025","article-title":"Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised hosts","volume":"257","author":"Erice","year":"1987","journal-title":"JAMA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1172\/JCI117648","article-title":"Mutations in human cytomegalovirus UL97 gene confer clinical resistance to ganciclovir and can be detected directly in patient plasma","volume":"95","author":"Wolf","year":"1995","journal-title":"J. Clin. Investig."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1128\/CMR.00023-08","article-title":"Neuropathogenesis of congenital cytomegalovirus infection: Disease mechanisms and prospects for intervention","volume":"22","author":"Cheeran","year":"2009","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_36","first-page":"e118874","article-title":"Comparative Effects of Valganciclovir and Ganciclovir on the Congenital Cytomegalovirus Infection and Hearing Loss: A Randomized Controlled Trial","volume":"32","author":"Yang","year":"2022","journal-title":"Iran. J. Pediatr."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1056\/NEJMoa1404599","article-title":"Valganciclovir for symptomatic congenital cytomegalovirus disease","volume":"372","author":"Kimberlin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/j.jcv.2009.08.012","article-title":"Neurodevelopmental outcomes following ganciclovir therapy in symptomatic congenital cytomegalovirus infections involving the central nervous system","volume":"46","author":"Oliver","year":"2009","journal-title":"J. Clin. Virol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1517\/17425255.2011.613824","article-title":"Cytomegalovirus antivirals and development of improved animal models","volume":"7","author":"McGregor","year":"2011","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Razonable, R.R., and Humar, A. (2019). Cytomegalovirus in solid organ transplant recipients\u2014Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. Clin. Transplant., 33.","DOI":"10.1111\/ctr.13512"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa011759","article-title":"A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis","volume":"346","author":"Martin","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/00003495-199652020-00006","article-title":"Cidofovir","volume":"52","author":"Lea","year":"1996","journal-title":"Drugs"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/978-1-4615-4743-3_10","article-title":"Cidofovir","volume":"5","author":"Safrin","year":"1999","journal-title":"Antivir. Chemother."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1093\/jpids\/pit048","article-title":"Ganciclovir, foscarnet, and cidofovir: Antiviral drugs not just for cytomegalovirus","volume":"2","author":"Upadhyayula","year":"2013","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2020-138685","article-title":"Cidofovir, a Choice for Salvage Treatment of CMV Infection in the Patients with Haploidentical Hematopoitic Stem Cell Transplantation","volume":"136","author":"Yin","year":"2020","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1128\/AAC.04348-14","article-title":"Pharmacokinetics and safety of intravenous cidofovir for life-threatening viral infections in pediatric hematopoietic stem cell transplant recipients","volume":"59","author":"Cohen","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_47","unstructured":"US Food & Drug Administration (2023, April 09). Orphan Drug Designations and Approvals, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/detailedIndex.cfm?cfgridkey=340211."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/femsre\/fuy004","article-title":"The human cytomegalovirus terminase complex as an antiviral target: A close-up view","volume":"42","author":"Ligat","year":"2018","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e13166","DOI":"10.1111\/tid.13166","article-title":"Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients","volume":"21","author":"Aryal","year":"2019","journal-title":"Transpl. Infect. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"ofac687","DOI":"10.1093\/ofid\/ofac687","article-title":"In Real-World Outcomes Associated with Letermovir Use for Cytomegalovirus Primary Prophylaxis in Allogeneic-Hematopoietic Cell Transplant Recipients: A Systematic Review and Meta-Analysis of Observational Studies","volume":"10","author":"Vyas","year":"2023","journal-title":"Open Forum Infect. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1073\/pnas.98.4.1895","article-title":"Distinct and separate roles for herpesvirus-conserved UL97 kinase in cytomegalovirus DNA synthesis and encapsidation","volume":"98","author":"Wolf","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/cid\/ciab988","article-title":"Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: Results from a phase 3 randomized clinical trial","volume":"75","author":"Avery","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40265-022-01677-4","article-title":"Maribavir: First approval","volume":"82","author":"Kang","year":"2022","journal-title":"Drugs"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.virol.2016.09.012","article-title":"Mood stabilizers inhibit cytomegalovirus infection","volume":"499","author":"Ornaghi","year":"2016","journal-title":"Virology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1097\/01.TP.0000122185.64004.89","article-title":"Leflunomide therapy for cytomegalovirus disease in renal allograft recepients","volume":"77","author":"John","year":"2004","journal-title":"Transplantation"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1016\/j.bbmt.2019.04.028","article-title":"Use of leflunomide for treatment of cytomegalovirus infection in recipients of allogeneic stem cell transplant","volume":"25","author":"Gokarn","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ijid.2020.06.087","article-title":"Onset of valganciclovir resistance in two infants with congenital cytomegalovirus infection","volume":"98","author":"Garofoli","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"104711","DOI":"10.1016\/j.antiviral.2020.104711","article-title":"Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance","volume":"176","author":"Chou","year":"2020","journal-title":"Antivir. Res."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Torii, Y., Horiba, K., Kawada, J.-i., Haruta, K., Yamaguchi, M., Suzuki, T., Uryu, H., Kashiwa, N., Goishi, K., and Ogi, T. (2022). Detection of antiviral drug resistance in patients with congenital cytomegalovirus infection using long-read sequencing: A retrospective observational study. BMC Infect. Dis., 22.","DOI":"10.1186\/s12879-022-07537-6"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1128\/iai.12.3.521-527.1975","article-title":"Candidate cytomegalovirus strain for human vaccination","volume":"12","author":"Plotkin","year":"1975","journal-title":"Infect. Immun."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0140-6736(74)92997-3","article-title":"Development of a vaccine against mental retardation caused by cytomegalovirus infection in utero","volume":"303","author":"Elek","year":"1974","journal-title":"Lancet"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"7437","DOI":"10.1016\/j.vaccine.2018.02.089","article-title":"Vaccination against the human cytomegalovirus","volume":"37","author":"Plotkin","year":"2019","journal-title":"Vaccine"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Scarpini, S., Morigi, F., Betti, L., Dondi, A., Biagi, C., and Lanari, M. (2021). Development of a vaccine against human cytomegalovirus: Advances, barriers, and implications for the clinical practice. Vaccines, 9.","DOI":"10.3390\/vaccines9060551"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41541-018-0074-4","article-title":"A new era in cytomegalovirus vaccinology: Considerations for rational design of next-generation vaccines to prevent congenital cytomegalovirus infection","volume":"3","author":"Nelson","year":"2018","journal-title":"NPJ Vaccines"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.cell.2009.01.035","article-title":"Origins and mechanisms of miRNAs and siRNAs","volume":"136","author":"Carthew","year":"2009","journal-title":"Cell"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.sbi.2005.05.006","article-title":"Post-transcriptional gene silencing by siRNAs and miRNAs","volume":"15","author":"Filipowicz","year":"2005","journal-title":"Curr. Opin. Struct. Biol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1038\/mtna.2015.23","article-title":"siRNA versus miRNA as therapeutics for gene silencing","volume":"4","author":"Lam","year":"2015","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"5660","DOI":"10.1128\/JVI.06338-11","article-title":"RNA interference-mediated targeting of human cytomegalovirus immediate-early or early gene products inhibits viral replication with differential effects on cellular functions","volume":"86","author":"Xiaofei","year":"2012","journal-title":"J. Virol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1073\/pnas.1719036115","article-title":"miRNA-mediated targeting of human cytomegalovirus reveals biological host and viral targets of IE2","volume":"115","author":"Schwarz","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1080\/21691401.2021.1890103","article-title":"Virus-associated ribozymes and nano carriers against COVID-19","volume":"49","year":"2021","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"14304","DOI":"10.1074\/jbc.272.22.14304","article-title":"Specific hammerhead ribozyme-mediated cleavage of mutant N-ras mRNA in vitro and ex vivo: Oligoribonucleotides as therapeutic agents","volume":"272","author":"Scherr","year":"1997","journal-title":"J. Biol. Chem."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Panda, K., Alagarasu, K., and Parashar, D. (2021). Oligonucleotide-based approaches to inhibit dengue virus replication. Molecules, 26.","DOI":"10.3390\/molecules26040956"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1080\/10409230600602634","article-title":"Ribonuclease P: The evolution of an ancient RNA enzyme","volume":"41","author":"Walker","year":"2006","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.omtn.2021.09.002","article-title":"The development and improvement of ribonucleic acid therapy strategies","volume":"26","author":"Zhao","year":"2021","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"5812","DOI":"10.1073\/pnas.100101797","article-title":"Effective inhibition of human cytomegalovirus gene expression and replication by a ribozyme derived from the catalytic RNA subunit of RNase P from Escherichia coli","volume":"97","author":"Trang","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1093\/nar\/gkh660","article-title":"RNase P ribozyme inhibits cytomegalovirus replication by blocking the expression of viral capsid proteins","volume":"32","author":"Kim","year":"2004","journal-title":"Nucleic Acids Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.3390\/v6062376","article-title":"Engineered RNase P ribozymes effectively inhibit human cytomegalovirus gene expression and replication","volume":"6","author":"Yang","year":"2014","journal-title":"Viruses"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1261\/rna.069682.118","article-title":"Inhibition of human cytomegalovirus major capsid protein expression and replication by ribonuclease P\u2013associated external guide sequences","volume":"25","author":"Deng","year":"2019","journal-title":"RNA"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Tripathi, S., Khatri, P., Fatima, Z., Pandey, R.P., and Hameed, S. (2023). A Landscape of CRISPR\/Cas Technique for Emerging Viral Disease Diagnostics and Therapeutics: Progress and Prospects. Pathogens, 12.","DOI":"10.3390\/pathogens12010056"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2147\/BTT.S326422","article-title":"Mechanism and applications of CRISPR\/Cas-9-mediated genome editing","volume":"15","author":"Asmamaw","year":"2021","journal-title":"Biol. Targets Ther."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Gergen, J., Coulon, F., Creneguy, A., Elain-Duret, N., Gutierrez, A., Pinkenburg, O., Verhoeyen, E., Anegon, I., Nguyen, T.H., and Halary, F.A. (2018). Multiplex CRISPR\/Cas9 system impairs HCMV replication by excising an essential viral gene. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0192602"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"van Diemen, F.R., Kruse, E.M., Hooykaas, M.J., Bruggeling, C.E., Sch\u00fcrch, A.C., van Ham, P.M., Imhof, S.M., Nijhuis, M., Wiertz, E.J., and Lebbink, R.J. (2016). CRISPR\/Cas9-mediated genome editing of herpesviruses limits productive and latent infections. PLoS Pathog., 12.","DOI":"10.1371\/journal.ppat.1005701"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1007\/s00705-020-04687-3","article-title":"Targeting human cytomegalovirus IE genes by CRISPR\/Cas9 nuclease effectively inhibits viral replication and reactivation","volume":"165","author":"Xiao","year":"2020","journal-title":"Arch. Virol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40778-014-0008-7","article-title":"Transcription activator-like effector (TALE) nucleases and repressor TALEs for antiviral gene therapy","volume":"1","author":"Bloom","year":"2015","journal-title":"Curr. Stem Cell Rep."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Chen, S.-J., and Chen, Y.-C. (2019). Potential application of TALENs against murine cytomegalovirus latent infections. Viruses, 11.","DOI":"10.3390\/v11050414"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"16281","DOI":"10.3390\/s150716281","article-title":"Nucleic acid aptamers: An emerging tool for biotechnology and biomedical sensing","volume":"15","author":"Ku","year":"2015","journal-title":"Sensors"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.omtn.2023.01.008","article-title":"Broadly neutralizing aptamers to SARS-CoV-2: A diverse panel of modified DNA antiviral agents","volume":"31","author":"Gelinas","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"48410","DOI":"10.1074\/jbc.M409059200","article-title":"A DNA aptamer prevents influenza infection by blocking the receptor binding region of the viral hemagglutinin","volume":"279","author":"Jeon","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"11902","DOI":"10.1128\/JVI.01378-09","article-title":"Inhibition of human cytomegalovirus replication via peptide aptamers directed against the nonconventional nuclear localization signal of the essential viral replication factor pUL84","volume":"83","author":"Kaiser","year":"2009","journal-title":"J. Virol."},{"key":"ref_90","first-page":"467","article-title":"A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS","volume":"133","author":"Group","year":"2002","journal-title":"Am. J. Ophthalmol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"865182","DOI":"10.3389\/fgene.2022.865182","article-title":"Innovative in Silico Approaches for Characterization of Genes and Proteins","volume":"13","author":"Bhat","year":"2022","journal-title":"Front. Genet."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1093\/nar\/gkx056","article-title":"Managing the sequence-specificity of antisense oligonucleotides in drug discovery","volume":"45","author":"Hagedorn","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"ref_93","first-page":"31","article-title":"Nanoparticles as delivery vehicles for antiviral therapeutic drugs","volume":"2","author":"Maus","year":"2021","journal-title":"Eng. Regen."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Jarach, N., Dodiuk, H., and Kenig, S. (2020). Polymers in the medical antiviral front-line. Polymers, 12.","DOI":"10.3390\/polym12081727"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Hawner, M., and Ducho, C. (2020). Cellular targeting of oligonucleotides by conjugation with small molecules. Molecules, 25.","DOI":"10.3390\/molecules25245963"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/6\/1358\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:53:32Z","timestamp":1760126012000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/6\/1358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,12]]},"references-count":95,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["v15061358"],"URL":"https:\/\/doi.org\/10.3390\/v15061358","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,12]]}}}